Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

704 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pomalidomide is active in the treatment of anemia associated with myelofibrosis.
Tefferi A, Verstovsek S, Barosi G, Passamonti F, Roboz GJ, Gisslinger H, Paquette RL, Cervantes F, Rivera CE, Deeg HJ, Thiele J, Kvasnicka HM, Vardiman JW, Zhang Y, Bekele BN, Mesa RA, Gale RP, Kantarjian HM. Tefferi A, et al. Among authors: verstovsek s. J Clin Oncol. 2009 Sep 20;27(27):4563-9. doi: 10.1200/JCO.2008.21.7356. Epub 2009 Aug 3. J Clin Oncol. 2009. PMID: 19652059 Free PMC article. Clinical Trial.
Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia.
Giles FJ, Kantarjian HM, Cortes JE, Garcia-Manero G, Verstovsek S, Faderl S, Thomas DA, Ferrajoli A, O'Brien S, Wathen JK, Xiao LC, Berry DA, Estey EH. Giles FJ, et al. Among authors: verstovsek s. J Clin Oncol. 2003 May 1;21(9):1722-7. doi: 10.1200/JCO.2003.11.016. J Clin Oncol. 2003. PMID: 12721247 Clinical Trial.
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase.
Giles FJ, Feldman EJ, Roboz GJ, Larson RA, Mamus SW, Cortes JE, Verstovsek S, Faderl S, Talpaz M, Beran M, Albitar M, O'Brien SM, Kantarjian HM. Giles FJ, et al. Among authors: verstovsek s. Leuk Res. 2003 Dec;27(12):1091-6. doi: 10.1016/s0145-2126(03)00094-8. Leuk Res. 2003. PMID: 12921945 Clinical Trial.
New approaches in the treatment of myelofibrosis.
Hennessy BT, Thomas DA, Giles FJ, Kantarjian H, Verstovsek S. Hennessy BT, et al. Among authors: verstovsek s. Cancer. 2005 Jan 1;103(1):32-43. doi: 10.1002/cncr.20752. Cancer. 2005. PMID: 15565565 Free article. Review.
Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia.
Quintas-Cardama A, Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Rios MB, Hayes K, Glassman A, Bekele BN, Zhou X, Cortes J. Quintas-Cardama A, et al. Among authors: verstovsek s. Blood. 2005 Mar 15;105(6):2281-6. doi: 10.1182/blood-2004-06-2208. Epub 2004 Nov 30. Blood. 2005. PMID: 15572595 Free article. Clinical Trial.
Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center.
Oki Y, Kantarjian HM, Zhou X, Cortes J, Faderl S, Verstovsek S, O'Brien S, Koller C, Beran M, Bekele BN, Pierce S, Thomas D, Ravandi F, Wierda WG, Giles F, Ferrajoli A, Jabbour E, Keating MJ, Bueso-Ramos CE, Estey E, Garcia-Manero G. Oki Y, et al. Among authors: verstovsek s. Blood. 2006 Feb 1;107(3):880-4. doi: 10.1182/blood-2005-06-2450. Epub 2005 Aug 25. Blood. 2006. PMID: 16123215 Free article.
A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia.
Giles F, Verstovsek S, Faderl S, Vey N, Karp J, Roboz G, Khan KD, Cooper M, Bilgrami SF, Ferrant A, Daenen S, Karsten V, Cahill A, Albitar M, Kantarjian H, O'Brien S, Feldman E. Giles F, et al. Among authors: verstovsek s. Leuk Res. 2006 Dec;30(12):1591-5. doi: 10.1016/j.leukres.2006.02.019. Epub 2006 Mar 29. Leuk Res. 2006. PMID: 16574225 Clinical Trial.
Thalidomide therapy for myelofibrosis with myeloid metaplasia.
Thomas DA, Giles FJ, Albitar M, Cortes JE, Verstovsek S, Faderl S, O'Brien SM, Garcia-Manero G, Keating MJ, Pierce S, Zeldis J, Kantarjian HM. Thomas DA, et al. Among authors: verstovsek s. Cancer. 2006 May 1;106(9):1974-84. doi: 10.1002/cncr.21827. Cancer. 2006. PMID: 16583431 Free article. Clinical Trial.
704 results